April 16, 2025 Nvidia’s $5.5B AI Chip Crunch and ASML’s Tariff Jitters
Apple: Dividend Growth Ahead, But a Near-Term Slide Likely
April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency
March 12, 2025 Features of exchanging USDC ERC20 to Bank Transfer
February 19, 2025 Why Stock Caps Matter When Building a Diversified Portfolio
February 5, 2025 Top 5 Coins for the Maximum Passive Income from Staking by 2024
January 21, 2025 Trading Stocks With AI: A Modern Approach
Deciphera Pharmaceuticals (DCPH) stock forecast for 2025
Updated: April 29, 2025 (03:12)
Sector: HealthcareThe share price of Deciphera Pharmaceuticals, Inc. (DCPH) now
50/200 Day Moving Average: $ / $
This figure corresponds to the Average Price over the previous 50/200 days. For Deciphera Pharmaceuticals stocks, the 50-day moving average is the support level today.
For Deciphera Pharmaceuticals stocks, the 200-day moving average is the support level today.
Are you interested in Deciphera Pharmaceuticals, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Deciphera Pharmaceuticals stock price in 2025. How much will one Deciphera Pharmaceuticals share be worth in 2025? Is it worth taking profit / loss on DCPH stock now or waiting? What are analysts' forecasts for Deciphera Pharmaceuticals stock?
We forecast Deciphera Pharmaceuticals stock performance using neural networks based on historical data on DCPH stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. This corporation stock prediction results are shown below and presented as a graph, table and text information.
Deciphera Pharmaceuticals, Inc. stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Deciphera Pharmaceuticals analysts is $. Today 200 Day Moving Average is the support level ( $). 50 Day Moving Average is the support level ( $).
Historical and forecast chart of Deciphera Pharmaceuticals, Inc. stock
The chart below shows the historical price of Deciphera Pharmaceuticals stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the DCPH stock price can be found in the table below.
Deciphera Pharmaceuticals, Inc. is a clinical research biopharmaceutical company.
The company develops drugs designed to improve the lives of cancer patients. Her drug candidates include DCC-2618, DCC-3014 and (Rebastinib) Rebastinib. The platform of kinase switching inhibitors developed by the Company suppresses the process of kinase activation. DCC-2618 is an orally administered inhibitor of kinase switching control for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas including glioblastoma multiforme (GBM), and other solid tumors caused by the pan-KIT or PDGFR gene alpha. DCC-3014 is an orally administered potent and highly selective colony stimulating factor receptor 1 (CSF1R) inhibitor. Rebastinib is a potent and selective oral immunokinase inhibitor of TIE2. Rebastinib binds tightly to the binding region (pocket) of the TIE2 switch, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.
Deciphera Pharmaceuticals (DCPH) Forecast for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| May | 23.18 | 20.50 | 24.81 | 17.38 % |
| Jun | 25.41 | 22.26 | 28.51 | 21.93 % |
| Jul | 27.24 | 25.28 | 28.82 | 12.29 % |
| Aug | 29.58 | 28.40 | 33.37 | 14.89 % |
| Sep | 25.32 | 22.39 | 27.80 | 19.49 % |
| Oct | 29.07 | 25.52 | 32.91 | 22.44 % |
| Nov | 28.43 | 23.88 | 32.52 | 26.57 % |
| Dec | 28.37 | 24.34 | 32.35 | 24.74 % |
Deciphera Pharmaceuticals information and performance
N/A
Market capitalization of the Deciphera Pharmaceuticals, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of DCPH shares in the company outstanding by the market price of one share.
EBITDA of Deciphera Pharmaceuticals is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Deciphera Pharmaceuticals price target for 2025 by month
Target values for the price of one Deciphera Pharmaceuticals share for May 2025.
In May, the Positive dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 17.383% volatility is expected.
Pessimistic target level: 20.50
Optimistic target level: 24.81
Target values for the price of one Deciphera Pharmaceuticals share for Jun 2025.
In Jun, the Positive dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 21.925% volatility is expected.
Pessimistic target level: 22.26
Optimistic target level: 28.51
Target values for the price of one Deciphera Pharmaceuticals share for Jul 2025.
In Jul, the Positive dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 12.287% volatility is expected.
Pessimistic target level: 25.28
Optimistic target level: 28.82
Target values for the price of one Deciphera Pharmaceuticals share for Aug 2025.
In Aug, the Positive dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 14.894% volatility is expected.
Pessimistic target level: 28.40
Optimistic target level: 33.37
Target values for the price of one Deciphera Pharmaceuticals share for Sep 2025.
In Sep, the Negative dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 19.490% volatility is expected.
Pessimistic target level: 22.39
Optimistic target level: 27.80
Target values for the price of one Deciphera Pharmaceuticals share for Oct 2025.
In Oct, the Positive dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 22.438% volatility is expected.
Pessimistic target level: 25.52
Optimistic target level: 32.91
Target values for the price of one Deciphera Pharmaceuticals share for Nov 2025.
In Nov, the Negative dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 26.574% volatility is expected.
Pessimistic target level: 23.88
Optimistic target level: 32.52
Target values for the price of one Deciphera Pharmaceuticals share for Dec 2025.
In Dec, the Negative dynamics for Deciphera Pharmaceuticals, Inc. shares will prevail with possible monthly volatility of 24.737% volatility is expected.
Pessimistic target level: 24.34
Optimistic target level: 32.35
